Literature DB >> 11959594

Effects of specific zidovudine resistance mutations and substrate structure on nucleotide-dependent primer unblocking by human immunodeficiency virus type 1 reverse transcriptase.

Peter R Meyer1, Suzanne E Matsuura, Adviye A Tolun, Ingrid Pfeifer, Antero G So, John W Mellors, Walter A Scott.   

Abstract

Nucleotide-dependent unblocking of chain-terminated DNA by human immunodeficiency virus type 1 reverse transcriptase (RT) is enhanced by the presence of mutations associated with 3'-azido-3'-deoxythymidine (AZT) resistance. The increase in unblocking activity was greater for mutant combinations associated with higher levels of in vivo AZT resistance. The difference between mutant and wild-type activity was further enhanced by introduction of a methyl group into the nucleotide substrate and was decreased for a nonaromatic substrate, suggesting that pi-pi interactions between RT and an aromatic structure may be facilitated by these mutations.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11959594      PMCID: PMC127181          DOI: 10.1128/AAC.46.5.1540-1545.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  Comparative enzymatic study of HIV-1 reverse transcriptase resistant to 2',3'-dideoxynucleotide analogs using the single-nucleotide incorporation assay.

Authors:  T Ueno; H Mitsuya
Journal:  Biochemistry       Date:  1997-02-04       Impact factor: 3.162

2.  Enhanced binding of azidothymidine-resistant human immunodeficiency virus 1 reverse transcriptase to the 3'-azido-3'-deoxythymidine 5'-monophosphate-terminated primer.

Authors:  B Canard; S R Sarfati; C C Richardson
Journal:  J Biol Chem       Date:  1998-06-05       Impact factor: 5.157

3.  Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase.

Authors:  P L Boyer; S G Sarafianos; E Arnold; S H Hughes
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

4.  Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2'-deoxynucleoside triphosphates.

Authors:  P R Meyer; S E Matsuura; R F Schinazi; A G So; W A Scott
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

5.  Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA.

Authors:  A Jacobo-Molina; J Ding; R G Nanni; A D Clark; X Lu; C Tantillo; R L Williams; G Kamer; A L Ferris; P Clark
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

6.  Kinetic mechanism of the DNA-dependent DNA polymerase activity of human immunodeficiency virus reverse transcriptase.

Authors:  J C Hsieh; S Zinnen; P Modrich
Journal:  J Biol Chem       Date:  1993-11-25       Impact factor: 5.157

7.  Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase.

Authors:  D Arion; N Kaushik; S McCormick; G Borkow; M A Parniak
Journal:  Biochemistry       Date:  1998-11-10       Impact factor: 3.162

8.  Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance.

Authors:  H Huang; R Chopra; G L Verdine; S C Harrison
Journal:  Science       Date:  1998-11-27       Impact factor: 47.728

9.  Mutagenic study of codons 74 and 215 of the human immunodeficiency virus type 1 reverse transcriptase, which are significant in nucleoside analog resistance.

Authors:  S F Lacey; B A Larder
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

10.  Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.

Authors:  P A Furman; J A Fyfe; M H St Clair; K Weinhold; J L Rideout; G A Freeman; S N Lehrman; D P Bolognesi; S Broder; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

View more
  28 in total

1.  The N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine.

Authors:  Matthew M Schuckmann; Bruno Marchand; Atsuko Hachiya; Eiichi N Kodama; Karen A Kirby; Kamalendra Singh; Stefan G Sarafianos
Journal:  J Biol Chem       Date:  2010-09-27       Impact factor: 5.157

2.  Chain-terminating dinucleoside tetraphosphates are substrates for DNA polymerization by human immunodeficiency virus type 1 reverse transcriptase with increased activity against thymidine analogue-resistant mutants.

Authors:  Peter R Meyer; Anthony J Smith; Suzanne E Matsuura; Walter A Scott
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

3.  Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision.

Authors:  Galina N Nikolenko; Sarah Palmer; Frank Maldarelli; John W Mellors; John M Coffin; Vinay K Pathak
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-31       Impact factor: 11.205

4.  Effect of translocation defective reverse transcriptase inhibitors on the activity of N348I, a connection subdomain drug resistant HIV-1 reverse transcriptase mutant.

Authors:  E Michailidis; K Singh; E M Ryan; A Hachiya; Y T Ong; K A Kirby; B Marchand; E N Kodama; H Mitsuya; M A Parniak; S G Sarafianos
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2012-12-22       Impact factor: 1.770

5.  Formation of a quaternary complex of HIV-1 reverse transcriptase with a nucleotide-competing inhibitor and its ATP enhancer.

Authors:  Maryam Ehteshami; Monique Nijhuis; Jean A Bernatchez; Christopher J Ablenas; Suzanne McCormick; Dorien de Jong; Dirk Jochmans; Matthias Götte
Journal:  J Biol Chem       Date:  2013-04-18       Impact factor: 5.157

6.  A role of template cleavage in reduced excision of chain-terminating nucleotides by human immunodeficiency virus type 1 reverse transcriptase containing the M184V mutation.

Authors:  Antonio J Acosta-Hoyos; Suzanne E Matsuura; Peter R Meyer; Walter A Scott
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

Review 7.  HIV-1 antiretroviral drug therapy.

Authors:  Eric J Arts; Daria J Hazuda
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

8.  Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.

Authors:  Paul L Boyer; Tomozumi Imamichi; Stefan G Sarafianos; Edward Arnold; Stephen H Hughes
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

9.  The Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.

Authors:  Antonio J Acosta-Hoyos; Walter A Scott
Journal:  Viruses       Date:  2010-01-28       Impact factor: 5.048

10.  The "Connection" Between HIV Drug Resistance and RNase H.

Authors:  Krista A Delviks-Frankenberry; Galina N Nikolenko; Vinay K Pathak
Journal:  Viruses       Date:  2010-07-01       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.